Threshold Pharmaceuticals Announces Detailed Results From Positive Phase 2b Trial of TH-302 in Pancreatic Cancer at AACR Annual Meeting
Threshold Pharmaceuticals, Inc. (NASDAQ: THLD) today announced that detailed results are now published in the abstract featuring its 214-patient randomized controlled Phase 2b clinical trial evaluating the efficacy and safety of two doses of TH-302, a hypoxia-targeted drug, in combination with gemcitabine compared to gemcitabine alone in patients with first-line advanced pancreatic cancer. The results will be presented by Mitesh J. Borad, M.D., a principal investigator and Assistant Professor of Medicine at the Mayo Clinic in Arizona, as part of a late breaking clinical trial presentation scheduled for 10:35 am CT on Monday, April 2, 2012, at the American Association of Cancer Research 2012 Annual Meeting in Chicago.
The presentation will be available in the publications section of www.thresholdpharm.com following the session. The abstract can be found on the aacr.org website or by clicking here.
(c) 2013 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.